Pharmaceutical giant Pfizer cite the use of HemaCare starting materials in the development of a new immune cell validation assay. 
The new assay is designed to measure dendritic cell activation as a predictor of immunogenicity, so that scientists can assess risk early in the development of new pharmaceuticals. Low immunogenicity points toward a better overall safety profile.
Dendritic cells (DC) are antigen-presenting cells, involved in the initiation and regulation of the immune response. Since DC are tumor-infiltrating cells central to the initiation of antigen-specific immunity, they have long been investigated as a means of improving cancer immunotherapy.